GlassScriptPhysician profile
Alexis N Davis
NPI 1275867640
$9,090.57
in general payments reported to CMS, 2019-2025
31 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,014 · 2022: $2,370 · 2023: $1,699 · 2024: $1,682 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,310 · Education: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.89 |
| Education | $396.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,380.51 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,054.66 | 2021-2025 | |
| Janssen Biotech, INC. | $763.46 | 2021-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $662.59 | 2021-2025 | Winlevi, Ilumya |
| Allergan, INC. | $617.84 | 2022 | |
| Genzyme Corporation | $490.21 | 2021-2025 | |
| Lilly USA, LLC | $447.19 | 2022-2025 | Taltz, Ebglyss |
| Pfizer INC. | $403.53 | 2021-2025 | |
| Ucb, INC. | $313.48 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $281.26 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $260.97 | 2021-2025 | Anzupgo, Adbry |
| Dermavant Sciences, INC. | $205.62 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $200.61 | 2022-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $193.99 | 2022-2024 | |
| Incyte Corporation | $122.28 | 2022-2025 | Opzelura |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $109.96 | 2021-2025 | Aklief, Oracea, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.46 | 2021-2024 | Arazlo, Jublia |
| Medimetriks Pharmaceuticals, INC. | $72.08 | 2022 | |
| Organon LLC | $70.18 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $60.51 | 2021 | |
| Sandoz INC. | $41.52 | 2023 | Hyrimoz |
| Almirall LLC | $39.97 | 2023 | Klisyri |
| Mayne Pharma Commercial LLC | $37.25 | 2021-2023 | |
| Organogenesis INC. | $30.71 | 2022 | |
| Biofrontera INC. | $26.91 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Misonix INC | $22.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.35 | 2024 | Cyltezo |
| Dermira, INC. | $18.21 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.45 | 2025 | Zoryve |
| Fresenius Kabi USA, LLC | $14.01 | 2024 | Idacio |
| Nabriva Therapeutics, Plc | $13.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.